Smart money already bought your next stock.

Key stats

Fundamentals Sep 10

Open: $98.50
52-wk high: $124.00
High: $98.64
52-wk low: $79.52
Low: $96.87
Prev close: $98.66
Mkt cap: $24.65B
Volume: 707.3K
Fwd P/E: 7.0x
Beta: 1.29
P/S: 9.3x
P/B: 1.2x
Profit margin: -63.6%
Op margin: -807.0%
ROE: -9.3%

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

8 funds hold a position and insiders have been net selling.

Funds

What funds are doing

8 moves · 6 mo

Buys/Adds$112.3MSells/Trims$102.2M

Buys/Adds (2)

BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$34.8M
added
P7
Point72
Steven Cohen · Q2 2026 13F
$30.4M
bought

Sells/Trims (1)

CI
Citadel
Ken Griffin · Q2 2026 13F
$50.6M
trimmed

5 more moves

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 moves

Coverage gaps for BNTX

No recent Congress trade
No recent market-voice mention

Other smart money signals

Activist stakes, short interest & more

1 item

SI
Short Interest ChangeModerate
short-volume tape softening: latest 14.1% fell 15.9pp vs 20d avg 30.0%

Reported Aug 4, 2026

Earnings came in 17.4% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Earnings per share

-$3.03-17.4%

-$2.58 expected

Next report

Reports Nov 2, 2026, in 53 days

EPS expected

$0.76

$0.39 to $1.35

Revenue expected

$1.06B

11 analysts

Last 30 days

3up0down

Analysts raising estimates

Estimate drift

+0.10

Change in 30 days

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -63.6%
Forward P/E: 7.04
Market cap: $24.7B

Valuation

P/S9.30
P/B1.20

Quality

Operating margin-807.0%
ROE-9.3%
ROA-5.4%

Growth

Beta1.29

Technicals

Price structure

This stock is trending upward, and looks oversold after a sharp drop.

Trend

Constructive

65 / 100

RSI 14

29oversold

20D volatility

85%annualized

52-week range

$98.13

$79.52$124.00

20D support

$90.52recent floor

20D resistance

$120.33recent ceiling

Returns

5D -3.7%20D +5.7%60D +8.4%

Price vs moving averages

SMA20 -5.0%SMA50 +1.4%SMA200 +0.5%

Volume pace

1.80xvs prior 20D

News

What the news says

7 articles · 7 days

Coverage leans bearish

1 bullish · 3 neutral · 3 bearish

Tone of tracked coverage

BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128
NeutralSep 8
BioNTech's Two-Speed Transition: Regulatory Wins Mask the Pain of a Portfolio in Retreat
Leans bearishSep 6
BioNTech's High-Stakes Seoul Debut: A Cash-Rich Pivot Meets Its First Real Test ()
NeutralSep 5
Is BioNTech Stock a No-Brainer Buy on the Dip?
Leans bullishSep 2
BioNTech Halts Phase 2 Trial of Individualized mRNA Cancer Vaccine Autogene Cevumeran in Colorectal Cancer
BearishSep 1
Autogene Cevumeran Trial Terminated in Resected Colorectal Cancer
BearishAug 31
BioNTech halts mRNA colorectal cancer vaccine trial after safety review
NeutralAug 28

10 macro signals shaping BNTX right now

Unlock sector rotation, regime shifts, and macro event windows tied to this stock.

Unlock the full results

BioNTech SE

Key stats

What do analysts expect?

What funds are doing

Activist stakes, short interest & more

Earnings came in 17.4% below what analysts expected.

Reports Nov 2, 2026, in 53 days

Is the business strong?

Price structure

What the news says

BioNTech SE

Key stats

What do analysts expect?

What funds are doing

Activist stakes, short interest & more

Earnings came in 17.4% below what analysts expected.

Reports Nov 2, 2026, in 53 days

Is the business strong?

Price structure

What the news says

BioNTech SE

Overview

Smart money

Earnings

Financials

Technicals

News

Macro

BioNTech SE

Overview

Smart money

Earnings

Financials

Technicals

News

Macro